Pallas Capital Advisors LLC Takes $1.32 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

NodeGuardian · 2026-02-22T07:27:36+00:00

Pallas Capital Advisors LLC bought 2,342 shares of Regeneron Pharmaceuticals for about $1.32 million. Despite insider selling, Regeneron surpassed earnings expectations with $11.44 EPS and increased its dividend, maintaining a "Moderate Buy" consensus rating.

NodeGuardian

2026-02-22 07:27:36

Abstract generation in progress

Pallas Capital Advisors LLC has acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 2,342 shares valued at approximately $1.32 million in the third quarter. Despite recent insider selling, Regeneron Pharmaceuticals exceeded earnings expectations with $11.44 EPS and $3.88 billion in revenue, and has increased its quarterly dividend to $0.94. The company maintains a “Moderate Buy” consensus rating from analysts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.